Homocysteine as a risk factor for cardiovascular disease: Should we (still) worry about it?

Swiss Medical Weekly

Volumn 136, Issue 47-48, 2006, Pages 745-756

  Faeh, David ^a,b   Chiolero, Arnaud ^a   Paccaud, Fred ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cardiovascular disease; Homocysteine; Risk factor; Screening; Treatment

Indexed keywords

CHOLESTEROL; FOLIC ACID; GLUCOSE; HOMOCYSTEINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DISEASE ASSOCIATION; DISEASE COURSE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HEALTH PRACTITIONER; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MORTALITY; NEURAL TUBE DEFECT; PREVALENCE; PROPHYLAXIS; PROTEIN METABOLISM; PROTEIN VARIANT; REVIEW; RISK FACTOR; SCREENING TEST; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 33846356782     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746-53.
2. Syme SL. Rethinking disease: where do we go from here? Ann Epidemiol. 1996;6(5):463-8.
3. Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50%" myth. Arch Intern Med. 2001;161(22):2657-60.
4. Beaglehole R, Magnus P. The search for new risk factors for coronary heart disease: occupational therapy for epidemiologists? Int J Epidemiol. 2002;31(6):1117-22; author reply 1134-1115W.
5. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). Jama. 1986;256(20):2823-8.
6. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47.
7. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000;72(2):324-32.
8. Kaplan ED. Association between homocyst(e)ine levels and risk of vascular events. Drugs Today. (Barc) 2003;39(3):175-92.
9. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. Jama. 2002;288(16):2015-22.
10. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol. 2002;31(1):59-70.
11. Beitz R, Mensink GB, Fischer B, Thamm M. Vitamins - dietary intake and intake from dietary supplements in Germany. Eur J Clin Nutr. 2002;56(6):539-45.
12. Genest J Jr. Hyperhomocyst(e)inemia - determining factors and treatment. Can J Cardiol. 1999;15(Suppl B):35B-38B.
13. Graham I. Homocysteine in health and disease. Ann Intern Med. 1999;131(5):387-88.
14. Moghadasian MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med. 1997;157(20):2299-308.
15. Oakley GP Jr. Eat right and take a multivitamin. N Engl J Med. 1998;338(15):1060-1.
16. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet. 1998;351 (9098):263.
17. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419.
18. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol. 2004;93(6):439-53.
19. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ. 1999;319(7224):1562-5.
20. Wilcken DE, Wang XL, Wilcken B. Methylenetetrahydrofolate reductase (MTHFR) mutation, homocyst(e)ine, and coronary artery disease. Circulation. 1997;96(8):2738-40.
21. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinaemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998;98(23):2520-6.
22. Bunout D, Hirsch S. Are we losing homocysteine as a cardiovascular risk factor? Nutrition. 2005;21(10):1068-9.
23. Guilland JC, Favier A, Potier de Courcy G, Galan P, Hercberg S. Hyperhomocysteinaemia: an independent risk factor or a simple marker of vascular disease? 2. Epidemiological data. Pathol Biol. (Paris) 2003;51(2):111-21.
24. Guilland JC, Favier A, Potier de Courcy G, Galan P, Hercberg S. Hyperhomocysteinaemia: an independent risk factor or a simple marker of vascular disease?. 1. Basic data. Pathol Biol. (Paris) 2003;51(2):101-10.
25. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005;331(7524):1053.
26. Eichholzer M, Tönz O, Zimmermann R. Folic acid: a public-health challenge. Lancet. 2006;367:13 52-61.
27. 1. American College ofMedical Genetics. Newborn Screening: Toward a Uniform Screening Panel and System. Final Report, March 8, 2005. http://mchb.hrsa.gov/screening/ (accessed: 2 May 2006).
28. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37(1):1-31.
29. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111-3.
30. Friso S, Girelli D, Trabetti E, Stranieri C, Olivieri O, Tinazzi E, et al. A1298C methylenetetrahydrofolate reductase mutation and coronary artery disease: relationships with C677T polymorphism and homocysteine/folate metabolism. Clin Exp Med. 2002;2(1):7-12.
31. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol. 1997;17(6):1157-62.
32. von Castel-Dunwoody KM, Kauwell GP, Shelnutt KP, Vaughn JD, Griffin ER, Maneval DR, et al. Transcobalamin 776C->G polymorphism negatively affects vitamin B-12 metabolism. Am J Clin Nutr. 2005;81(6):1436-41.
33. Selhub J, Jacques PF, Bostom AG, Wilson PW, Rosenberg IH. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification. Public Health Rev. 2000;28(1-4):117-45.
34. Hughes K, Ong CN. Homocysteine, folate, vitamin Bi2, and cardiovascular risk in Indians, Malays, and Chinese in Singapore. J Epidemiol Community Health. 2000;54(1):31-4.
35. de Bree A, van der Put NM, Mennen LI, Verschuren WM, Blom HJ, Galan P, et al. Prevalences of hyperhomocysteinaemia, unfavorable cholesterol profile and hypertension in European populations. Eur J Clin Nutr. 2005;59(4):480-8.
36. McCully KS. Vascular pathology of homocysteinaemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111-28.
37. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest. 1976;57(4):1079-82.
38. Ray JG. Meta-analysis of hyperhomocysteinaemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998;158(19):2101-6.
39. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinaemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80(6):874-7.
40. Bottiglieri T. Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005.
41. Tucker KL, Qiao N, Scott T, Rosenberg I, Spiro A, 3rd. High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am J Clin Nutr. 2005;82(3):627-35.
42. Ravaglia G, Forti P, Maioli F, Scali RC, Saccheitti L, Talerico T, et al. Homocysteine and cognitive performance in healthy-elderly subjects. Arch Gerontol Geriatr. Suppl 2004;(9):349-57.
43. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr. 2005;82(3):636-43.
44. Bottiglieri T. Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(7):1103-12.
45. Ramos MI, Allen LH, Haan MN, Green R, Miller JW. Plasma folate concentrations are associated with depressive symptoms in elderly Latina women despite folic acid fortification. Am J Clin Nutr. 2004;80(4):1024-8.
46. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346(7):476-83.
47. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol. 2003;2(7):425-8.
48. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, Bottiglieri T, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol. 2004;61(6):865-8.
49. Vignini A, Nanetti L, Bacchetti T, Ferretti G, Curatola G, Mazzanti L. Modification induced by homocysteine and low-density lipoprotein on human aortic endothelial cells: an in vitro study. J Clin Endocrinol Metab. 2004;89(9):4558-61.
50. Su SJ, Huang LW, Pai LS, Liu HW, Chang KL. Homocysteine at pathophysiologic concentrations activates human monocyte and induces cytokine expression and inhibits macrophage migration inhibitory factor expression. Nutrition. 2005;21(10):994-1002.
51. Demuth K, Atger V, Borderie D, Benoit MO, Sauvaget D, Lotersztajn S, et al. Homocysteine decreases endothelin-1 production by cultured human endothelial cells. Eur J Biochem. 1999;263(2):367-76.
52. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol. 2000;279(4):F671-78.
53. Brown JC, Rosenquist TH, Monaghan DT. ERK2 activation by homocysteine in vascular smooth muscle cells. Biochem Biophys Res Commun. 1998;251(3):669-76.
54. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993;13(9):1327-33.
55. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272(27):17012-7.
56. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91(1):308-18.
57. Foncea R, Carvajal C, Almarza C, Leighton F. Endothelial cell oxidative stress and signal transduction. Biol Res. 2000;33(2):89-96.
58. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, et al. Hyperhomocysteinaemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107(6):675-83.
59. Bellamy MF, McDowell IF. Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis. 1997;20(2):307-15.
60. Lentz SR, Erger RA, Dayal S, Maeda N, Malinow MR, Heistad DD, et al. Folate dependence of hyperhomocysteinaemia and vascular dysfunction in cystathionine beta-synthase-deficient mice. Am J Physiol Heart Circ Physiol. 2000;279(3):H970-5.
61. Namekata K, Enokido Y, Ishii I, Nagai Y, Harada T, Kimura H. Abnormal lipid metabolism in cystathionine beta-synthase-deficient mice, an animal model for hyperhomocysteinaemia. J Biol Chem. 2004;279(51):52961-9.
62. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinaemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet. 2001;10(5):433-43.
63. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr. 1996;126(4 Suppl):1285S-9S.
64. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost. 2005;3(8):1646-54.
65. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med. 2001;161(5):695-700.
66. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. Jama. 1995;274(13):1049-57.
67. Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. Jama. 1996;276(23):1879-85.
68. Hickling S, Hung J, Knuiman M, Jamrozik K, McQuillan B, Beilby J, et al. Impact of voluntary folate fortification on plasma homocysteine and serum folate in Australia from 1995 to 2001: a population based cohort study. J Epidemiol Community Health. 2005;59(5):371-6.
69. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol. 2001;21(12):2080-5.
70. Moat SJ, Hill MH, McDowell IF, Pullin CH, Ashfield-Watt PA, Clark ZE, et al. Reduction in plasma total homocysteine through increasing folate intake in healthy individuals is not associated with changes in measures of antioxidant activity or oxidant damage. Eur J Clin Nutr. 2003;57(3):483-9.
71. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ. 1998;316(7135):894-8.
72. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999;99(1):178-82.
73. National Nutrient Database for Standard Reference of the US Department of Agriculture (USDA, release 18). http://www.nal.usda.gov/fnic/foodcomp/srch/ search.htm (accessed: 20 March 2006).
74. de Bree A, van Dusseldorp M, Brouwer IA, van het Hof KH, Steegers-Theunissen RP. Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr. 1997;51(10):643-60.
75. Spoelstra-de MA, Brouwer CB, Terheggen F, Bollen JM, Stehouwer CD, Smulders YM. No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia. Neth J Med. 2004;62(7):246-53.
76. De Luca G, Suryapranata H, Gregorio G, Lange H, Chiariello M. Homocysteine and its effects on in-stent restenosis. Circulation. 2005;112(19):e307-311.
77. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350(26):2673-81.
78. Kluijtmans LA, Kastelein JJ, Lindemans J, Boers GH, Heil SG, Bruschke AV, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997;96(8):2573-7.
79. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365(9455):224-32.
80. Nitsch D, Molokhia M, Smeeth L, DeStavola BL, Whittaker JC, Leon DA. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol. 2006;163(5):397-403.
81. Bostom AG, Culleton BF. Hyperhomocysteinaemia in chronic renal disease. J Am Soc Nephrol. 1999;10(4):891-900.
82. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. Jama. 1995;274{19):1526-33.
83. Bostom AG. Homocysteine: "expensive creatinine" or important modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients? J Am Soc Nephrol. 2000;11(1):149-51.
84. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol. 2000;11(1):134-7.
85. Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol. 1996;77(9):759-61.
86. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol. 1996;143(9):845-59.
87. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med. 1995;237(4):381-8.
88. Hultberg B, Andersson A, Lindgren A. Marginal folate deficiency as a possible cause of hyperhomocystinaemia in stroke patients. Eur J Clin Chem Clin Biochem. 1997;35(1):25-8.
89. Loehrer FM, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S-adenosylmethionine and correlation between 5- methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol. 1996;16(6):727-33.
90. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995;26(5):795-800.
91. Hirsch S, Ronco AM, Vasquez M, de la Maza MP, Garrido A, Barrera G, et al. Hyperhomocysteinaemia in healthy young men and elderly men with normal serum folate concentration is not associated with poor vascular reactivity or oxidative stress. J Nutr. 2004;134(7):1832-5.
92. Hirsch S, de la Maza P, Mendoza L, Petermann M, Glasinovic A, Paulinelli P, et al. Endothelial function in healthy younger and older hyperhomocysteinemic subjects. J Am Geriatr Soc. 2002;50(6):1019-23.
93. Dusitanond P, Eikelboom JW, Hankey GJ, Thom J, Gilmore G, Loh K, et al. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. Stroke. 2005;36(1):144-6.
94. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. Jama. 2003;290(7):932-40.
95. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. Jama. 2004;291(5):565-75.
96. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567-77.
97. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-88.
98. Eichholzer M, Tonz O, Zimmermann R. Folic acid: a public-health challenge. Lancet. 2006;367(9519):1352-61.
99. Pfeiffer CM, Caudill SP, Gunter EW, Osterloh J, Sampson EJ. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. Am J Clin Nutr. 2005;82(2):442-50.
100. Husemoen LL, Thomsen TF, Fenger M, Jorgensen T. Changes in lifestyle and total homocysteine in relation to MTHFR(C677T) genotype: the Inter99 study. Eur J Clin Nutr 2005.
101. Rousseau AS, Robin S, Roussel AM, Ducros V, Margaritis I. Plasma homocysteine is related to folate intake but not training status. Nutr Metab Cardiovasc Dis. 2005;15(2):125-33.
102. Hankey GJ. Secondary prevention of recurrent stroke. Stroke. 2005;36(2):218-21.
103. Potena L, Grigioni F, Magnani G, Ortolani P, Coccolo F, Sassi S, et al. Homocysteine-lowering therapy and early progression of transplant vasculopathy: a prospective, randomized, IVUS-based study. Am J Transplant. 2005;5(9):2258-64.
104. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114(1):82-96.
105. 12 and elevated homocysteine. Asia Pac J Clin Nutr. 2004;13(Suppl):S85.
106. 12 status in healthy Iranian adults: the Tehran homocysteine survey (2003-2004)/ a cross - sectional population based study. BMC Public Health. 2006;6(1):29.
107. 12, serum folate, and red cell folate levels in relation to plasma homocysteine: is a preventable public health issue on the rise? Clin Biochem. 2000;33(5):337-43.
108. Shaw JT, McWhinney B, Tate JR, Kesting JB, Marczak M, Purdie D, et al. Plasma homocysteine levels in indigenous Australians. Med J Aust. 1999;170(1):19-22.
109. Janson JJ, Galarza CR, Murua A, Quintana I, Przygoda PA, Waisman G, et al. Prevalence of hyperhomocysteinemia in an elderly population. Am J Hypertens. 2002;15(5):394-7.
110. 12 status in Korean adults. J Nutr Sci Vitaminol. (Tokyo) 2002;48(4):290-7.
111. 12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis. 2000;10(4):195-203.
112. Neal B, MacMahon S, Ohkubo T, Tonkin A, Wilcken D. Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. Eur Heart J. 2002;23(19):1509-15.
113. The VTTATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002;13(2):120-6.
114. Hankey GJ, Eikelboom JW, Loh K, Tang M, Pizzi J, Thom J, et al. Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population. Cerebrovasc Dis. 2005;19(2):110-6.
115. Bassuk SS, Albert CM, Cook NR, Zaharris E, MacFadyen JG, Danielson E, et al. The Women's Antioxidant Cardiovascular Study: design and baseline characteristics of participants. J Womens Health. (Larchmt) 2004;13(1):99-117.
116. Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J. 2006;152(3):448-53.
117. Bleie O, Refsum H, Ueland PM, Vollset SE, Guttormsen AB, Nexo E, et al. Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention. Am J Clin Nutr. 2004;80(3):641-8.
118. 12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging. 2003;7(6):428-35.
119. Jamison RL, Hartigan P, GazianoJM, Fortmann SP, Goldfarb DS, Haroldson JA, et al. Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. Clin Trials. 2004;1(5):451-60.
120. Baker F, Picton D, Blackwood S, HuntJ, Erskine M, Dyas M. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation. 2002;106(3642 (abstract)).
121. U.S. Preventive Services Task Force. Routine vitamin supplementation to prevent cancer and cardiovascular disease: recommendations and rationale. Am Fam Physician. 2003;68 (12):2422-4.
122. International Task Force for Prevention of Coronary Heart Disease. http://www.chd-taskforce.de/guidelines/kap23.htm (accessed: 3 May 2006).
123. AHA (American Heart Association) & CDC (Centers of Disease Control and Prevention). http://www.americanheart. org/presenter.jhtml?identifier=4677 (accessed: 3 May 2006).
124. National Guideline Clearinghouse. Preventive health care: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. http://guideline.gov/summary/pdf.aspx?doc_id=2702&stat= 1&string= (accessed: 3 May 2006). 2000.